GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2008

AMRI Lands a $4M Milestone Fee from Bristol-Myers Squibb

  • AMRI is due to receive a $4 million milestone payment from Bristol-Myers Squibb as a result of submitting an application to the Canadian regulatory agency to begin Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. A Clinical Trial Application was filed with the Health Products and Food Branch, Health Canada.

    The compound under consideration is a biogenic amine reuptake inhibitor acting at multiple targets. AMRI and Bristol-Myers Squibb have collaborated to develop treatments for depression and diseases of the central nervous system.
    This is the second milestone for this first candidate to emerge from the partnership; AMRI announced a $1.5 million fee a year ago when this compound was nominated by BMS for development.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »